GeneDx Holdings Corp. reported $454M of revenue over the trailing twelve months, +25% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $454M (to Q2 2026). Net income: −$106M, trailing twelve months to Q2 2026. Free cash flow: −$76M, trailing twelve months to Q2 2026. Operating margin: −22%, trailing twelve months to Q2 2026.

WGSGeneDx Holdings Corp.

Healthcare

$67.31-48% 1Y

$67.31

$34.5152 weeks$167.51

WGS as reported

GeneDx Holdings Corp. reported $454M of revenue over the trailing twelve months, +25% on the year before. 10 reported series are charted on this page, each one as filed.

$454M

Revenue, trailing twelve months · to Q2 2026 · +25% against the twelve months before

Net income: −$106M
Net income · −7665% year on year · trailing twelve months to Q2 2026
Free cash flow: −$76M
Free cash flow · −9232% year on year · trailing twelve months to Q2 2026
Operating margin: −22%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for WGS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$454M	+25%	Q2 2026
Net income	−$106M	−7665%	Q2 2026
EPS	−$3.64	−7380%	Q2 2026
Gross margin	69%	n/a	Q2 2026
Operating margin	−22%	n/a	Q2 2026
Net margin	−25%	n/a	Q2 2026
ROE	−20%	n/a	Q2 2026
ROA	−10%	n/a	Q2 2026
ROIC	−16%	n/a	Q2 2026
Free cash flow	−$76M	−9232%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.